(Q39038837)

8 September 2017

title

Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients (English)

1 reference

8 September 2017

16

Atsushi Ochiai

1 reference

8 September 2017

3

Takeshi Kuwata

1 reference

8 September 2017

15

Takayuki Yoshino

1 reference

8 September 2017

17

Atsushi Ohtsu

1 reference

8 September 2017

13

Kohei Shitara

1 reference

8 September 2017

8

Satoshi Yuki

1 reference

8 September 2017

12

Takeharu Yamanaka

1 reference

8 September 2017

5

Shigenori Kadowaki

1 reference

8 September 2017

6

Eiji Shinozaki

1 reference

8 September 2017

4

Tomohiro Nishina

1 reference

8 September 2017

10

Shinya Kajiura

1 reference

8 September 2017

1

Nozomu Fuse

1 reference

8 September 2017

2

Yasutoshi Kuboki

1 reference

8 September 2017

7

Nozomu Machida

1 reference

8 September 2017

Akiko Kawano Nagatsuma

series ordinal

14

object named as

Akiko Kawano Nagatsuma

1 reference

8 September 2017

Akira Ooki

9

1 reference

8 September 2017

Tetsuo Kimura

series ordinal

11

1 reference

8 September 2017

publication date

15 February 2015

1 reference

8 September 2017

1 reference

8 September 2017

volume

19

1 reference

8 September 2017

issue

1

1 reference

8 September 2017

page(s)

183-191

1 reference

https://scigraph.springernature.com/pub.10.1007/s10120-015-0471-6

8 September 2017

exact match

0 references

cites work

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0471-6

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0471-6

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0471-6

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0471-6

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0471-6

c-erbB-2 proto-oncogene expression and its relationship to survival in gastric carcinoma: an immunohistochemical study on archival material.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0471-6

Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0471-6

EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0471-6

High expression of HER3 is associated with a decreased survival in gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0471-6

Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0471-6

Overexpression of the c-met protooncogene in human gastric carcinoma--correlation to clinical features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0471-6

MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0471-6

MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0471-6

Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0471-6

The clinicopathologic association of c-MET overexpression in Iranian gastric carcinomas; an immunohistochemical study of tissue microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0471-6

Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0471-6

Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0471-6

Classification of adenocarcinoma of the oesophagogastric junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0471-6

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0471-6

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0471-6

Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0471-6

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0471-6

Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0471-6

Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0471-6

Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10120-015-0471-6

c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems

21 January 2018

1 reference

12 December 2020

HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series.

1 reference

12 December 2020

Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer

1 reference

12 December 2020

c-Met expression in gastric cancer with liver metastasis

1 reference

12 December 2020

The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas

1 reference

12 December 2020

Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery

1 reference

12 December 2020

Expression of {beta}-catenin, MUC1 and c-met in diffuse-type gastric carcinomas: correlations with tumour progression and prognosis.

1 reference

12 December 2020

MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy

1 reference

12 December 2020

The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor

1 reference

12 December 2020

Correlation between overexpression of c-met gene and the progression of gastric cancer

1 reference

12 December 2020

Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features

1 reference

12 December 2020

10.1007/S10120-015-0471-6

Identifiers

DOI

1 reference

release_rprumwqr4fdplc7bg4lzza3j5u

8 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rprumwqr4fdplc7bg4lzza3j5u

24 November 2022

mapped directly with Wikidata item

1 reference